A Randomized, Double Blind, Phase 2 Study to Assess the Safety and Immunogenicity of Three Formulations of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) in Healthy Adults
Phase of Trial: Phase II
Latest Information Update: 14 Jul 2017
Price : $35 *
At a glance
- Drugs TAK 003 (Primary)
- Indications Dengue
- Focus Pharmacodynamics
- Sponsors Takeda
- 12 Nov 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
- 11 Sep 2014 Status changed from not yet recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 07 Aug 2014 New trial record